186
Views
2
CrossRef citations to date
0
Altmetric
Open Peer Commentaries

Fairness in Manufacturing Cellular Therapies

, &
 
This article refers to:
Ethical Guidance for Selecting Clinical Trials to Receive Limited Space in an Immunotherapy Production Facility

CONFLICTS OF INTEREST

Pilar Ossorio is on the ethics advisory board for Astellas Pharma U.S., Inc. She has received less than $3000 in consulting fees from Astellas each year for the past two years. To the best of her knowledge, Astellas has no active immunotherapy products on the market or in development. Astellas does have a regenerative medicine, cell therapy product in development in the US (described on the firm's website). Krishanu Saha is a member of the forum on Regenerative Medicine (NASEM) and the Center for Cell Manufacturing (CMaT, NSF). These organizations provided reimbursement for travel expenses for meetings related to immunotherapy manufacturing.

Additional information

Funding

KS was supported by the National Institutes of Health (R35GM119644), National Science Foundation (EEC-1648035), National Science Foundation (CBET-1350178).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.